Lunresertib

Lunresertib (RP-6306) is a potent, selective and orally active PKMYT1 inhibitor with an IC50 of 14 nM. lunresertib shows a high degree of selectivity over other kinases in cellular binding assays. lunresertib shows anticancer effects[1].

Product Specifications

CAS Number

[2719793-90-3]

Product Name Alternative

RP-6306

UNSPSC

12352005

Target

Wee1

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rp-6306.html

Purity

99.97

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(C1=C(N)[N@]([C@]2=C(C)C(O)=CC=C2C)C3=NC(C)=C(C)C=C31)N

Molecular Formula

C18H20N4O2

Molecular Weight

324.38

References & Citations

[1]Janek Szychowski, et al. Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306. J Med Chem. 2022 Aug 11;65 (15) :10251-10284. |[2]David Gallo, et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature. 2022 Apr;604 (7907) :749-756.